Comparative Pharmacology
Head-to-head clinical analysis: BENADRYL versus EVALOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENADRYL versus EVALOSE.
BENADRYL vs EVALOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine; inverse agonist at histamine H1 receptors, blocking histamine-induced vasodilation, increased capillary permeability, and bronchoconstriction; also anticholinergic and sedative.
EVALOSE is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity by blocking the reuptake of serotonin at the presynaptic neuron, thereby increasing serotonin levels in the synaptic cleft.
25-50 mg orally every 4-6 hours as needed; maximum 300 mg per day. Alternatively, 10-50 mg intramuscularly or intravenously once, maximum 100 mg per dose (IV route preferred).
Adults: 1-2 tablets (5-10 mg) orally once daily, adjusted to maximum 20 mg/day.
None Documented
None Documented
Terminal elimination half-life 4-8 hours; prolonged in hepatic impairment (up to 20 hours).
Terminal elimination half-life is 12 hours (range 10-14 h); clinically significant for once-daily dosing in most patients with normal renal function; extend dosing interval in renal impairment
Renal (90% as metabolites, <5% unchanged); minimal biliary/fecal.
Renal: 70% unchanged; Biliary/Fecal: 20% as metabolites; 10% other
Category C
Category C
Antihistamine
Antihistamine